Rare Blood Disorders
Explore facts and recommendations for pharmacological treatments for rare blood disorders.
We didn't find any resources that match your selection.
Please adjust your filter(s) and try again.
Risk Mitigation During Concizumab Prophylaxis in Phase 3 Clinical Trials in Patients With Hemophilia A/B With and Without Inhibitors
This poster reviews the risk mitigation strategy and breakthrough bleed management guidance for patients treated with concizumab in clinical trials.
Improved Quality of Life and Satisfaction With N8-GP in US Patients
This poster reviews the health-related quality of life and satisfaction in US patients with severe hemophilia A receiving N8-GP in the pathfinder trials.
Longitudinal Efficacy and Safety of N9-GP for Prophylaxis and Bleed Control in US Patients
This poster reviews the efficacy and safety of N9-GP in US patients on prophylactic and on-demand therapy.
Emerging Non-Factor Therapies for Hemophilia
Mechanism of action for emerging therapies to treat hemophilia without using replacement coagulation factor.
Continuing Education
Find accredited opportunities in rare blood disorders education.
Rare Blood Disorders
Rare Blood Disorders
Looking for additional resources?
Explore other libraries or search the Exchange.
Additional Information
Speak to a live medical representative.
If you are a healthcare provider from the United States, click below to request information directly from the Novo Nordisk Medical Information department. If you are a patient, please visit https://www.novonordisk-us.com/contact-us.html or call 1-800-727-6500
Search the Medical Information Database
The Scientific Exchange is a resource for U.S. Healthcare Professionals to learn more about disease states investigated by Novo Nordisk and our related products.
Scientific Exchange is a trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.
